Psoriatic arthritis (PsA) is distinguished from other forms of inflammatory arthritis by unique pathophysiology and manifestations. Important developments for rheumatologists and rheumatology professionals to note include the release of a new PsA treatment guideline in early 2019, the development of patient outcome measures and studies that have demonstrated that tight control of disease activity leads to improvements in these outcome measures for patients. In this resource center, you’ll find our summary of the guideline, as well as a collection of important research reviews, case reports and clinical articles on advances in the diagnosis and management of PsA.
FEATURED ARTICLE: PsA Treatment Guideline: recommendations for first-line therapy and more
